Vaccines Category Lead - Middle East

ROLE SUMMARY The Vaccines Category Lead - Middle East is a strategic member of the Middle East Leadership Team, accountable for the end-to-end strategy, performance and long-term value of Pfizer’s vaccines portfolio across the cluster. The role translates enterprise vaccine priorities into differentiated market strategies, balances current portfolio delivery with future growth, and ensures disciplined choices across brands, markets, customer segments and investments. The role leads the vaccines marketing organization and orchestrates new launches, commercial opportunities aligned with public-health immunization priorities and priority vaccine accelerators. Working across Commercial, Medical, Access & Value, Policy & Public Affairs, Regulatory, Supply, Finance and market teams, the role creates the conditions for successful launch adoption, broader immunization access and sustainable category growth across diverse Middle East healthcare systems. CORE ACCOUNTABILITIES 1. CATEGORY STRATEGY & PORTFOLIO LEADERSHIP ·       Own and translate the Middle East vaccines strategy into clear portfolio, brand, market and customer priorities aligned with the cluster operating plan and growth agenda. ·       Lead end-to-end portfolio planning across established vaccines, growth assets, new indications and future launches, balancing near-term delivery with long-term category value. ·       Set differentiated market strategies reflecting local epidemiology, immunization pathways, customer needs, access conditions and competitive dynamics. ·       Establish category governance, operating rhythms and performance reviews that connect regional strategy with market execution. 2. BUSINESS & P&L LEADERSHIP ·       Own category business performance and provide clear direction on revenue, market share, investment, profitability and resource-deployment priorities. ·       Lead annual operating plan and long-range planning for the vaccines portfolio, ensuring robust assumptions, scenarios, risks and growth choices. ·       Prioritize A&P and commercial investments across assets and markets, reallocating resources toward the highest-impact opportunities. ·       Monitor performance and intervene early where launch, demand, access, supply or execution risks threaten category objectives. 3. NEW LAUNCHES & PIPELINE READINESS ·       Lead integrated launch strategy and readiness for new vaccines, indications and presentations across Middle East markets. ·       Define launch ambition, sequencing, market archetypes, customer strategy, investment requirements and critical success factors. ·       Build cross-functional launch plans spanning regulatory, medical, access, policy, supply, marketing, sales and customer engagement. ·       Track launch readiness and post-launch performance through clear milestones and governance; accelerate decisions and remove execution barriers. 4. Commercial Opportunities aligned with & PUBLIC-SECTOR GROWTH ·       Identify and prioritize potential commercial opportunities for Pfizer vaccines arising from the inclusion, expansion or optimization of  the public- health immunization programs and coordinate appropriate internal assessment and execution in accordance with Pfizer policies and procedures. ·       Partner with Access & Value, Medical and Policy & Public Affairs to develop evidence-based value propositions and coordinated stakeholder engagement plans supporting commercial opportunities aligned with public-health immunization needs, in accordance with Pfizer policies and procedures. ·       Shape market-specific pathways that address public-health needs, evidence requirements, funding considerations, procurement processes and implementation readiness. ·       Maintain an enterprise view of commercial opportunities and associat